Instem Stock Price, News & Analysis (LON:INS)

GBX 178 0.00 (0.00 %)
(As of 01/19/2018 05:07 AM ET)
Previous CloseGBX 178
Today's RangeGBX 178 - GBX 178
52-Week RangeGBX 140 - GBX 235
VolumeN/A
Average Volume3,065 shs
Market Capitalization£28.46 million
P/E Ratio8,900.00
Dividend YieldN/A
BetaN/A

About Instem (LON:INS)

Instem logoInstem plc is a supplier of information technology (IT) applications to the early development healthcare market delivering solutions for data collection, management and analysis across the research and development continuum. The Company is engaged in Global Life Sciences operations. Its lead product suite, Provantis, is an application in the Early Development Safety Assessment (EDSA) market. The Provantis solution incorporates a suite of modules required for managing and recording EDSA studies, from receipt of the compound through to the automated assembly of statistical analyses and final reports. Its software allows scientific staff to collect, analyze and share data across the organization and externally. It also offers ALPHADAS, an early phase clinical software solution. The Company offers Centrus suite, which provides pre-built applications, as well as the ability to utilize a range of business intelligence and analysis tools.

Receive INS News and Ratings via Email

Sign-up to receive the latest news and ratings for INS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry IT Services & Consulting
Sub-IndustryN/A
SectorIT Services & Consulting - NEC
SymbolLON:INS
CUSIPN/A
Phone+44-1785-825600

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio8900
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX 0.02
Net IncomeN/A
Net Margins-6.81%
Return on Equity-11.22%
Return on Assets-4.84%

Miscellaneous

EmployeesN/A
Outstanding Shares15,890,000

Instem (LON:INS) Frequently Asked Questions

What is Instem's stock symbol?

Instem trades on the London Stock Exchange (LON) under the ticker symbol "INS."

Who are some of Instem's key competitors?

Who are Instem's key executives?

Instem's management team includes the folowing people:

  • Philip John Reason, Chief Executive Officer, Executive Director
  • Nigel John Goldsmith, Chief Financial Officer, Company Secretary, Executive Director
  • MaryBeth Thompson, Chief Operating Officer
  • David Gare, Non-Executive Chairman of the Board
  • David M. Sherwin, Non-Executive Director
  • Michael Frederick McGoun, Non-Executive Independent Director (Age 65)

How do I buy Instem stock?

Shares of Instem and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Instem's stock price today?

One share of Instem stock can currently be purchased for approximately GBX 178.

How big of a company is Instem?

Instem has a market capitalization of £28.46 million.

How can I contact Instem?

Instem's mailing address is Diamond Way, Stone Business Park, STONE, ST15 0SD, United Kingdom. The company can be reached via phone at +44-1785-825600.


MarketBeat Community Rating for Instem (INS)

Community Ranking:  1.0 out of 5 (star)
Outperform Votes:  31 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  149
MarketBeat's community ratings are surveys of what our community members think about Instem and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Instem (LON:INS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A

Instem (LON:INS) Consensus Price Target History

Price Target History for Instem (LON:INS)

Instem (LON:INS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
9/19/2016N+1 SingerReiterated RatingCorporateView Rating Details
(Data available from 1/19/2016 forward)

Earnings

Earnings History for Instem (LON:INS)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Instem (LON:INS) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Instem (LON:INS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Instem (LON INS) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Instem (LON:INS)

Instem (LON INS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/23/2016Sherwin,DavidInsiderSell200,000GBX 200£400,000
(Data available from 1/1/2013 forward)

Headlines

Instem (LON INS) News Headlines

Source:

SEC Filings

Instem (LON:INS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Instem (LON INS) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.